Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes

New Preservative-Free and pH-Balanced Products Formulated for Irritated, Dry Eyes

Now Rolling out to Major U.S. Retailers

- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health"), today announced the U.S. launch of Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes. Both products are preservative-free and uniquely formulated with naturally inspired ingredients to relieve symptoms associated with irritated, dry eyes.

"One of the major culprits of dry eyes, which is one of the most common eye conditions in the United States 1 , is our increasing usage of digital devices. We developed Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes to provide instant moisture to help relieve dry, digital-device-weary eyes," said Joe Gordon , U.S. president, Bausch + Lomb. "Inspired by the biology of the eye, both products are free of preservatives and are pH-balanced."

Biotrue ® Hydration Boost Lubricant Eye Drops, which can be used while wearing soft contact lenses,* provide instant moisture and relief for irritated, dry eyes. These eye drops are pH-balanced to match healthy tears with ingredients that include an electrolyte, a component of natural, healthy tears, an antioxidant, to protect against free radicals, and hyaluronan (HA) 2 , a moisturizer found naturally in tears.

For some patients, eyelid buildup can be associated with irritated, dry eyes. Bausch + Lomb developed Biotrue ® Micellar Eyelid Cleansing Wipes to gently cleanse and hydrate the eyelid area to help eyes feel more comfortable. Similar to the Biotrue ® Hydration Boost Lubricant Eye Drops, the cleansing wipes are formulated with ingredients that include HA and an electrolyte as well as a micellar cleanser comprised of a naturally derived surfactant for gentle cleansing and aloe, licorice and dandelion root extract, which are naturally soothing.

"Many of my patients report having tired and irritated eyes at the end of the day, which is typically the result of prolonged digital device usage that can lead to eye dryness," said Jennifer Tsai , O.D., and founder, Line of Sight, New York . "The availability of Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes offers two convenient, over-the-counter options that I look forward to offering my patients to help relieve the symptoms of their dry, digitally irritated eyes."

Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes will be available for purchase in the eye care aisle or online at most national retailers, including Walgreens, CVS, Walmart, Target, Rite Aid and Amazon. Both will have a manufacturer's suggested retail price as low as $11.99 .

For more information on the Biotrue ® family of products, visit www.biotrue.com .

About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.com .

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

References
1. Multi-sponsor Surveys, Inc., The 2017 Gallup Study of Dry Eye Sufferers.
2. HA is sourced from a large-scale natural fermentation process.

*Based on standardized testing of soft contact lenses. Not meant to lubricate or rewet lenses.

®/TM are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other product/brand names and/or logos are trademarks of the respective owners.
© 2021 Bausch & Lomb Incorporated or its affiliates.
BTW.0026.USA.21

Bausch Health Investor Contact:

Bausch Health Media Contact:

Arthur Shannon

Lainie Keller

arthur.shannon@bauschhealth.com

lainie.keller@bauschhealth.com

(514) 865-3855

(908) 927-1198

(877) 281-6642 (toll free)


Biotrue® Hydration Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes

(PRNewsfoto/Bausch Health Companies)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/bausch--lomb-launches-biotrue-hydration-boost-lubricant-eye-drops-and-biotrue-micellar-eyelid-cleansing-wipes-301331203.html

SOURCE Bausch Health Companies Inc.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Medtronic: Americans Favor Quality Over Quantity in Pursuit of Longevity

According to a new survey from Medtronic and Morning Consult, nearly two-thirds of U.S. adults say they'd opt for a shorter, healthier life than a longer one with health issues

Americans overwhelmingly say that when they think about longevity, it's more than just living longer - it's about living their healthiest, best lives. While most want to live to 90-well past the average U.S. life expectancy of 77.5 years-nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues. These findings, from a survey conducted by global healthcare technology leader Medtronic with Morning Consult, highlight a gap between U.S. adults' desire to live healthier years and the opportunity for more people to improve their quality of life through healthcare technology

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cardiex Limited

Cardiex Limited


Keep reading...Show less

Americans favor quality over quantity in pursuit of longevity

According to a new survey from Medtronic and Morning Consult, nearly two-thirds of U.S. adults say they'd opt for a shorter, healthier life than a longer one with health issues

Americans overwhelmingly say that when they think about longevity, it's more than just living longer—it's about living their healthiest, best lives. While most want to live to 90—well past the average U.S. life expectancy of 77.5 years—nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues. These findings, from a survey conducted by global healthcare technology leader Medtronic with Morning Consult, highlight a gap between U.S. adults' desire to live healthier years and the opportunity for more people to improve their quality of life through healthcare technology.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×